Conference abstracts
Compliance with digital therapeutics programs may result in better outcomes and diabetes management through long-term behavior change. This study analyzed and showed the effectiveness of higher compliance to Diabefly® program being associated with higher reduction in HbA1c levels, significant improvement in glycemic control and motivation for self-management of diabetes. This is evident from the results of 56 individuals showing an effective reduction in HbA1c levels by 1.94% from the baseline and compliance score was positively correlated with this reduction. Further, a remarkable improvement in motivational score from a baseline score of 33.43±4.29 to 36.93±4.83 was observed.